Objective:To investigate the expression and the regulation effect of cell growth of microRNA-577 in hepatocellular carcinoma(HCC).Methods:qRT-PCR was applied to detect the relative expression of miR-577 in 70 paired H...Objective:To investigate the expression and the regulation effect of cell growth of microRNA-577 in hepatocellular carcinoma(HCC).Methods:qRT-PCR was applied to detect the relative expression of miR-577 in 70 paired HCC and matched tumor adjacent tissues collecting from resection between March 2011 and March 2014.Pearson chi-square test was used to analyze the relationship between the miR-577 expression and clinical features.The miR-577 mimics were transfected into HepG2 cells:cell cycles were detected by flow cytometry,cell proliferation was measured by MTT assay and BrdU incorporation assay,and cell apoptosis was determined by flow cytometry and Caspase 3/7 activity analysis.The expressions ofβ-catenin were measured by immunohistochemistry.Spearman correlation analysis was used to analyze the relationship between miR-577 and p-catenin.qRT-PCR and westernblot were used to detect the expression of p-catenin in transfected HepG2 cells.Results:The relative expressions of miR-577 was significantly lower in HCC tissues compared to the matched normal tumor-adjacent tissues(P<0.05).Low expression of miR-577 was significantly associated with large tumor size(≥5 cm,P<0.05) and advanced tumor node metastasis stage(Ⅲ+Ⅳ,P<0.05).Transfection of miR-577 mimics could inhibit repress cell proliferation,enhance cell apoptosis and block the cell cycles in G_1/G_1 phase(P<0.05).miR-577 in HCC group had a significant negative correlation relationship with the expression of downstream target of β-catenin(P<0.05).Both the mRNA and protein expression in HepG2 cells were down-regulated after transfection(P<0.05).Conclusions:Low expression of miR-577 is related to the malignant clinicopathological features in HCC tissues,and miR-577 may suppress HCC growth through down-regulating p-catenin.展开更多
目的探讨miR-577在幼儿复发性喉乳头状瘤中的表达及其对细胞增殖、侵袭的影响和潜在分子机制。方法收集2016年6月至2019年12月确诊的30例幼儿喉乳头状瘤组织样本及其相匹配且远离病灶经病理检查证实的正常喉组织样本,并选取人正常喉上...目的探讨miR-577在幼儿复发性喉乳头状瘤中的表达及其对细胞增殖、侵袭的影响和潜在分子机制。方法收集2016年6月至2019年12月确诊的30例幼儿喉乳头状瘤组织样本及其相匹配且远离病灶经病理检查证实的正常喉组织样本,并选取人正常喉上皮细胞株和喉乳头状瘤细胞(分为miR-577过表达组、阴性对照组及空白对照组)进行研究。采用实时荧光定量PCR(qRT-PCR)分别检测30例喉乳头状瘤组织、配对正常喉组织、正常喉上皮细胞和喉乳头状瘤细胞中miR-577相对表达;通过Lipofectamine^(TM)3000脂质体转染试剂盒将miR-577 mimic模拟物转染至喉乳头状瘤细胞构建miR-577过表达细胞系,采用CCK-8法、Tanswell实验分别检测miR-577对喉乳头状瘤细胞增殖、侵袭的影响;采用Western blot检测miR-577对喉乳头状瘤细胞侵袭相关蛋白(MMP-1、MMP-9)表达及Notch通路相关蛋白(Notch、DSL)表达的影响。结果幼儿喉乳头状瘤组织中miR-577相对表达量(0.134±0.026)显著低于正常喉组织(0.823±0.056)(P<0.001);喉乳头状瘤细胞中miR-577相对表达量(0.256±0.026)显著低于正常喉上皮细胞(0.962±0.072)(P<0.001);与阴性对照组相比,转染miR-577 mimic后喉乳头状瘤细胞增殖能力(1.248±0.103 vs 0.902±0.094)和细胞侵袭率(71.016±5.869 vs 42.867±4.795)明显降低(P<0.05);侵袭相关蛋白MMP-1(1.011±0.124 vs 0.417±0.056)、MMP-9(1.012±0.155 vs 0.502±0.058)表达抑制(P<0.01)。喉乳头状瘤细胞中Notch、DSL表达显著上调(P<0.05);转染miR-577 mimic后喉乳头状瘤细胞中Notch通路相关蛋白Notch、DSL表达明显抑制(P<0.05)。共转染miR-577 mimic和pcDNA3.1-Notch后喉乳头状瘤细胞增殖能力和细胞侵袭率较单纯转染miR-577 mimic组明显增加(P<0.05);共转染pcDNA3.1-Notch逆转了miR-577 mimic对喉乳头状瘤细胞增殖、侵袭能力的抑制作用。结论幼儿喉乳头状瘤组织及喉乳头状瘤细胞中miR-577显著低表达,过表达miR-577显著抑制喉乳头状瘤细胞的增殖和侵袭;Notch是miR-577的潜在靶点,miR-577可能通过与Notch的3'UTR区结合进而调控Notch信号通路来抑制喉乳头状瘤细胞的增殖和侵袭。展开更多
目的:探讨利用577nm阈值下微脉冲激光治疗糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析48例64眼DME患者临床资料,行577nm阈值下微脉冲激光术者26例35眼,行传统格栅样激光术者22例29眼。比较术前及术后1、3、6mo时BCVA(LogMAR)、...目的:探讨利用577nm阈值下微脉冲激光治疗糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析48例64眼DME患者临床资料,行577nm阈值下微脉冲激光术者26例35眼,行传统格栅样激光术者22例29眼。比较术前及术后1、3、6mo时BCVA(LogMAR)、黄斑中心凹视网膜厚度(CFT)、平均光敏感度(MS)及平均视野缺损(MD)变化,分析两组患者眼底硬性渗出持续时间及并发症。结果:术后1、3、6mo时,两组视力(0.30±0.09 vs 0.35±0.10、0.19±0.07 vs 0.26±0.09、0.13±0.04 vs 0.18±0.05)及CFT (349.26±21.80μm vs 364.37±23.91μm、314.46±20.49μm vs 335.07±22.68μm、328.35±21.74μm vs 352.43±23.60μm)均较术前下降,且观察组明显低于同一时间对照组(均P<0.05);观察组MS、MD水平均较术前提升,且明显高于同一时间对照组5.83±1.16dB vs 4.22±1.04dB、6.38±1.29dB vs 4.49±1.17dB、6.75±1.22dB vs 4.68±1.20dB,-5.53±1.41dB vs-7.66±1.52dB、-5.09±1.30dB vs-7.26±1.39dB、-4.68±1.14dB vs-7.05±1.26dB)(均P<0.05)。观察组眼底硬性渗出持续时间明显少于对照组(3.39±0.80mo vs 4.25±1.14mo)(P<0.05)。术后6mo内,观察组眼球疼痛发生率明显低于对照组[3%(1/35)vs 24%(7/29)](P<0.05),而前房炎性反应、视野缺损、高眼压及角膜水肿发生率比较均无差异(P>0.05)。结论:577nm阈值下微脉冲激光术治疗DME安全有效。展开更多
目的:分析577nm微脉冲激光(SML)光凝联合玻璃体腔注射康柏西普治疗增殖性糖尿病视网膜病变(PDR)患者玻璃体切除术后发生糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析2019-01/2021-06就诊于我院经玻璃体切除治疗的PDR患者,术后发生...目的:分析577nm微脉冲激光(SML)光凝联合玻璃体腔注射康柏西普治疗增殖性糖尿病视网膜病变(PDR)患者玻璃体切除术后发生糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析2019-01/2021-06就诊于我院经玻璃体切除治疗的PDR患者,术后发生DME患者29例30眼。根据治疗方式不同分为两组,单纯注射组患者14例14眼行玻璃体腔注射康柏西普,联合治疗组患者15例16眼行黄斑区577nm微脉冲激光光凝联合玻璃体腔注射康柏西普。比较两组患者治疗前及治疗6、12mo最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)的变化,以及治疗前、治疗12mo多焦视网膜电流图(mfERG)的变化。结果:两组患者治疗6、12mo BCVA(LogMAR)均较术前改善,CMT均较术前下降(均P<0.001)。单纯注射组治疗前及治疗6、12mo BCVA(LogMAR)、CMT与联合治疗组比较均无差异(均P>0.05)。治疗12mo单纯注射组较联合治疗组振幅略低(23.02±3.13 vs 26.50±3.33μV/deg2),潜伏期延长(38.75±1.62 vs 34.21±3.06ms)(均P≤0.001)。随访12mo,单纯注射组注射康柏西普8.14±1.46次,联合治疗组5.05±1.51次(P<0.05)。结论:577nm微脉冲激光光凝联合玻璃体腔注射康柏西普可有效缓解玻璃体切除术后DME患者的黄斑水肿、提高BCVA,并能改善黄斑区视功能,有效减少康柏西普注射次数。展开更多
基金Supported by Heilongjiang Province Science Foundation for YouthQC2009C110
文摘Objective:To investigate the expression and the regulation effect of cell growth of microRNA-577 in hepatocellular carcinoma(HCC).Methods:qRT-PCR was applied to detect the relative expression of miR-577 in 70 paired HCC and matched tumor adjacent tissues collecting from resection between March 2011 and March 2014.Pearson chi-square test was used to analyze the relationship between the miR-577 expression and clinical features.The miR-577 mimics were transfected into HepG2 cells:cell cycles were detected by flow cytometry,cell proliferation was measured by MTT assay and BrdU incorporation assay,and cell apoptosis was determined by flow cytometry and Caspase 3/7 activity analysis.The expressions ofβ-catenin were measured by immunohistochemistry.Spearman correlation analysis was used to analyze the relationship between miR-577 and p-catenin.qRT-PCR and westernblot were used to detect the expression of p-catenin in transfected HepG2 cells.Results:The relative expressions of miR-577 was significantly lower in HCC tissues compared to the matched normal tumor-adjacent tissues(P<0.05).Low expression of miR-577 was significantly associated with large tumor size(≥5 cm,P<0.05) and advanced tumor node metastasis stage(Ⅲ+Ⅳ,P<0.05).Transfection of miR-577 mimics could inhibit repress cell proliferation,enhance cell apoptosis and block the cell cycles in G_1/G_1 phase(P<0.05).miR-577 in HCC group had a significant negative correlation relationship with the expression of downstream target of β-catenin(P<0.05).Both the mRNA and protein expression in HepG2 cells were down-regulated after transfection(P<0.05).Conclusions:Low expression of miR-577 is related to the malignant clinicopathological features in HCC tissues,and miR-577 may suppress HCC growth through down-regulating p-catenin.
文摘目的探讨miR-577在幼儿复发性喉乳头状瘤中的表达及其对细胞增殖、侵袭的影响和潜在分子机制。方法收集2016年6月至2019年12月确诊的30例幼儿喉乳头状瘤组织样本及其相匹配且远离病灶经病理检查证实的正常喉组织样本,并选取人正常喉上皮细胞株和喉乳头状瘤细胞(分为miR-577过表达组、阴性对照组及空白对照组)进行研究。采用实时荧光定量PCR(qRT-PCR)分别检测30例喉乳头状瘤组织、配对正常喉组织、正常喉上皮细胞和喉乳头状瘤细胞中miR-577相对表达;通过Lipofectamine^(TM)3000脂质体转染试剂盒将miR-577 mimic模拟物转染至喉乳头状瘤细胞构建miR-577过表达细胞系,采用CCK-8法、Tanswell实验分别检测miR-577对喉乳头状瘤细胞增殖、侵袭的影响;采用Western blot检测miR-577对喉乳头状瘤细胞侵袭相关蛋白(MMP-1、MMP-9)表达及Notch通路相关蛋白(Notch、DSL)表达的影响。结果幼儿喉乳头状瘤组织中miR-577相对表达量(0.134±0.026)显著低于正常喉组织(0.823±0.056)(P<0.001);喉乳头状瘤细胞中miR-577相对表达量(0.256±0.026)显著低于正常喉上皮细胞(0.962±0.072)(P<0.001);与阴性对照组相比,转染miR-577 mimic后喉乳头状瘤细胞增殖能力(1.248±0.103 vs 0.902±0.094)和细胞侵袭率(71.016±5.869 vs 42.867±4.795)明显降低(P<0.05);侵袭相关蛋白MMP-1(1.011±0.124 vs 0.417±0.056)、MMP-9(1.012±0.155 vs 0.502±0.058)表达抑制(P<0.01)。喉乳头状瘤细胞中Notch、DSL表达显著上调(P<0.05);转染miR-577 mimic后喉乳头状瘤细胞中Notch通路相关蛋白Notch、DSL表达明显抑制(P<0.05)。共转染miR-577 mimic和pcDNA3.1-Notch后喉乳头状瘤细胞增殖能力和细胞侵袭率较单纯转染miR-577 mimic组明显增加(P<0.05);共转染pcDNA3.1-Notch逆转了miR-577 mimic对喉乳头状瘤细胞增殖、侵袭能力的抑制作用。结论幼儿喉乳头状瘤组织及喉乳头状瘤细胞中miR-577显著低表达,过表达miR-577显著抑制喉乳头状瘤细胞的增殖和侵袭;Notch是miR-577的潜在靶点,miR-577可能通过与Notch的3'UTR区结合进而调控Notch信号通路来抑制喉乳头状瘤细胞的增殖和侵袭。
文摘目的:探讨利用577nm阈值下微脉冲激光治疗糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析48例64眼DME患者临床资料,行577nm阈值下微脉冲激光术者26例35眼,行传统格栅样激光术者22例29眼。比较术前及术后1、3、6mo时BCVA(LogMAR)、黄斑中心凹视网膜厚度(CFT)、平均光敏感度(MS)及平均视野缺损(MD)变化,分析两组患者眼底硬性渗出持续时间及并发症。结果:术后1、3、6mo时,两组视力(0.30±0.09 vs 0.35±0.10、0.19±0.07 vs 0.26±0.09、0.13±0.04 vs 0.18±0.05)及CFT (349.26±21.80μm vs 364.37±23.91μm、314.46±20.49μm vs 335.07±22.68μm、328.35±21.74μm vs 352.43±23.60μm)均较术前下降,且观察组明显低于同一时间对照组(均P<0.05);观察组MS、MD水平均较术前提升,且明显高于同一时间对照组5.83±1.16dB vs 4.22±1.04dB、6.38±1.29dB vs 4.49±1.17dB、6.75±1.22dB vs 4.68±1.20dB,-5.53±1.41dB vs-7.66±1.52dB、-5.09±1.30dB vs-7.26±1.39dB、-4.68±1.14dB vs-7.05±1.26dB)(均P<0.05)。观察组眼底硬性渗出持续时间明显少于对照组(3.39±0.80mo vs 4.25±1.14mo)(P<0.05)。术后6mo内,观察组眼球疼痛发生率明显低于对照组[3%(1/35)vs 24%(7/29)](P<0.05),而前房炎性反应、视野缺损、高眼压及角膜水肿发生率比较均无差异(P>0.05)。结论:577nm阈值下微脉冲激光术治疗DME安全有效。
文摘目的:分析577nm微脉冲激光(SML)光凝联合玻璃体腔注射康柏西普治疗增殖性糖尿病视网膜病变(PDR)患者玻璃体切除术后发生糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析2019-01/2021-06就诊于我院经玻璃体切除治疗的PDR患者,术后发生DME患者29例30眼。根据治疗方式不同分为两组,单纯注射组患者14例14眼行玻璃体腔注射康柏西普,联合治疗组患者15例16眼行黄斑区577nm微脉冲激光光凝联合玻璃体腔注射康柏西普。比较两组患者治疗前及治疗6、12mo最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)的变化,以及治疗前、治疗12mo多焦视网膜电流图(mfERG)的变化。结果:两组患者治疗6、12mo BCVA(LogMAR)均较术前改善,CMT均较术前下降(均P<0.001)。单纯注射组治疗前及治疗6、12mo BCVA(LogMAR)、CMT与联合治疗组比较均无差异(均P>0.05)。治疗12mo单纯注射组较联合治疗组振幅略低(23.02±3.13 vs 26.50±3.33μV/deg2),潜伏期延长(38.75±1.62 vs 34.21±3.06ms)(均P≤0.001)。随访12mo,单纯注射组注射康柏西普8.14±1.46次,联合治疗组5.05±1.51次(P<0.05)。结论:577nm微脉冲激光光凝联合玻璃体腔注射康柏西普可有效缓解玻璃体切除术后DME患者的黄斑水肿、提高BCVA,并能改善黄斑区视功能,有效减少康柏西普注射次数。
